Norway· NO-ID_A162B438-092D-4654-BD7B-7CC1A6ED9AED
Xolair
A omalizumab product containing omalizumab, registered in Norway by Novartis. The same ATC class is registered in 16 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Omalizumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX05 (omalizumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Omalizumab · ATC R03DX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of omalizumab costs, country by country.
Normalised to the WHO defined daily dose (16 mg), the median price runs from $0.26 in Czechia to $48.02 in Switzerland — a ×186 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Omalizumab · price per daily dose (16 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.02
- CZ Czechia$0.26
The record
At a glance
FEST (Norway)- Active substance
- Omalizumab
- Manufacturer
- Novartis
- Country
- Norway (NO)
- ATC code
- R03DX05
- ATC class
- Omalizumab
- Defined daily dose
- 16 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 2
- no_merkevare_idID_A162B438-092D-4654-BD7B-7CC1A6ED9AED
- no_varenummer306684150
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for omalizumab.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Omalizumab · interactions on record
8 records
- 1 moderate
- 7 minor
Most severe, free to view
- Omacetaxine mepesuccinateL01XX40moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Omalizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumXolair 150 mgNovartis Europharm
- SpainXOLAIR 150 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLENovartis Europharm Limited
- United KingdomXolair 150mg powder and solvent for solution for injection vialsNovartis Pharmaceuticals UK Ltd
- IcelandXolairNovartis Europharm Limited*
- PolandXolairNovartis Europharm Limited
- SwedenXolair 150 mg Pulver och vätska till injektionsvätska, lösningNovartis Europharm Limited
- CzechiaOMLYCLOCelltrion Healthcare Hungary Kft., Budapest
- FinlandOmlycloCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Omlyclo, Xolair
- Liechtenstein · Omlyclo, Xolair
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d4865b5d-901a-456f-9952-df81d1eb0402 GET /v1/drugs/d4865b5d-901a-456f-9952-df81d1eb0402?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Omalizumab",
"merkevare_id": "ID_A162B438-092D-4654-BD7B-7CC1A6ED9AED",
"name_form_strength": "Xolair pulv til inj væske, oppl 150 mg",
"prescription_group": "C"
}See everything about omalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.